ALKS stock forecast, quote, news & analysis
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas... Show more
Alkermes (ALKS) Stock Analysis: Sleep Medicine Push Gains Momentum
Key Takeaways
- Alkermes completed its acquisition of Avadel Pharmaceuticals, adding LUMRYZ to its portfolio and accelerating entry into the sleep medicine market.
- Q4 2025 earnings showed revenue beating estimates at $384.5 million, though EPS missed; full-year 2025 revenue reached $1.48 billion.
- 2026 guidance projects total revenue of $1.73–$1.84 billion and adjusted EBITDA of $370–$410 million, driven by proprietary products.
- CEO Richard Pops to step down, with a succession plan announced alongside earnings.
- Orexin agonist alixorexton (ALKS 2680) advances to Phase 3 for narcolepsy, supported by FDA Breakthrough Therapy Designation.
- Analysts maintain a consensus "Buy" rating with an average price target of $43.65, implying significant upside from current levels.
Current Market Snapshot
Alkermes (ALKS) stock has navigated volatility in recent trading sessions amid key corporate developments, trading around $27 with a market cap near $4.5 billion. The shares reflect a 52-week range of $25.17 to $36.32, underscoring resilience in the biopharma sector. Proprietary neuroscience products like VIVITROL, ARISTADA, and LYBALVI continue to drive steady demand, bolstered by the recent integration of Avadel's LUMRYZ for narcolepsy treatment. Investor sentiment balances growth potential in sleep disorders against near-term profitability pressures from acquisition-related costs. Analyst targets suggest optimism for expansion in neurological therapies.
Trending AI Robots
Tickeron’s Trending AI Robots page features a curated selection of over 25 high-performing AI trading bots, drawn from hundreds available on the platform that analyze and trade thousands of tickers across stocks, ETFs, and crypto. These bots employ advanced technical and fundamental analyses, real-time signals, and risk management to outperform the market, with trending ones spotlighted for their adaptability to current volatility in sectors like energy, semiconductors, and aerospace. Performance stats are compelling: annualized returns range from +17% to over +216%, win rates from 53% to 95%, and profit factors up to 22.58, with some managing up to 25 tickers simultaneously. Each bot varies in strategy—from short-term scalping (1-day holds) to longer swings (up to 62 days)—catering to diverse styles and risk tolerances. Explore these top performers to enhance your trading edge in dynamic conditions.
Recent Developments Driving ALKS Price Action
Alkermes plc (ALKS), a biopharmaceutical firm specializing in neuroscience therapies, has seen its stock influenced by transformative events over recent weeks. The standout catalyst was the February 2026 completion of its $2.1–$2.37 billion acquisition of Avadel Pharmaceuticals, adding FDA-approved LUMRYZ (sodium oxybate extended-release) for narcolepsy to the portfolio. This deal, initially announced in October 2025 and sweetened amid competition from Lundbeck, expands Alkermes' footprint in sleep medicine, projecting $315–$335 million in LUMRYZ net sales for 2026. The move synergizes with Alkermes' orexin receptor agonist pipeline, positioning the company for commercial launches in hypersomnolence disorders.
On February 25, 2026, Alkermes released Q4 and full-year 2025 results: quarterly revenue hit $384.5 million (beating estimates by $3 million), driven by proprietary products, though GAAP EPS of $0.29 missed the $0.38 consensus. Full-year revenue dipped 5.1% to $1.48 billion amid manufacturing shifts, but profitability remained solid with $394 million adjusted EBITDA. Guidance for 2026 outlined total revenue of $1.73–$1.84 billion (up ~20%), proprietary sales $1.52–$1.60 billion (VIVITROL $460–$480M, ARISTADA $365–$385M, LYBALVI $380–$400M), adjusted EBITDA $370–$410 million, offset by a GAAP net loss of $115–$135 million from acquisition accounting like $150 million inventory step-up. Despite the revenue beat, shares fell ~7% post-earnings on the EPS miss and weaker 2025 trends, amplifying concerns over integration costs and $1.525 billion term debt (due 2031).
Concurrently, long-time CEO Richard Pops announced his departure after three decades, with a succession plan unveiled, sparking biopharma leadership transition discussions. This fueled short-term selling pressure amid execution risks.
Pipeline momentum bolstered sentiment: alixorexton (formerly ALKS 2680) received FDA Breakthrough Therapy Designation and end-of-Phase 2 feedback, paving for Q1 2026 Phase 3 initiation in narcolepsy (Vibrance-1/2 complete). Phase 2 in idiopathic hypersomnia wraps Q4 2026, with early orexin candidates (ALKS 7290, 4510) eyeing Phase 2 in ADHD and fatigue. Recent presentations at TD Cowen highlighted this pivot, while the March 11 announcement of the inaugural Alkermes Pathways APN Research Awards and Stifel CNS Forum fireside chat (March 17) signal R&D commitment. Analyst reactions mixed: Wells Fargo raised target to $43 (Overweight), H.C. Wainwright trimmed on guidance, RBC held Buy; consensus Buy at $43.65 average target.
Price action linked directly: post-acquisition and earnings dip reflected dilution/debt fears, but pipeline catalysts and sales visibility stabilized shares around $27, down from $36 peaks.
2026 Outlook and Key Factors to Monitor
As Alkermes integrates Avadel and scales its neuroscience franchise through 2026, investors should track proprietary product execution, particularly LUMRYZ ramp-up amid narcolepsy market growth, alongside VIVITROL alcohol dependence demand and LYBALVI/ARISTADA schizophrenia share gains. Revenue guidance of $1.73–$1.84 billion assumes 20%+ growth, with manufacturing/royalties at $210–$240 million post-XEPLION phase-out. R&D spend rises to $445–$485 million for alixorexton's Phase 3 Brilliance program in narcolepsy, idiopathic hypersomnia readout, and orexin Phase 2 starts in ADHD/MS/Parkinson's fatigue—milestones that could validate the sleep pipeline.
Risks include acquisition synergies, debt repayment via cash flows ($1.3 billion starting liquidity), and inventory amortization impacting GAAP losses. Regulatory progress on orexin agonists, competitive pressures in antipsychotics/opioids, and CEO transition execution loom large. Broader biopharma trends like CNS innovation and hypersomnolence unmet needs offer tailwinds, balanced against cost controls and capital allocation. Upcoming catalysts: Q1 earnings (late April), Phase 3 initiations, and conference updates will shape trajectory.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Aroon Indicator for ALKS shows an upward move is likely
ALKS's Aroon Indicator triggered a bullish signal on May 18, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 208 similar instances where the Aroon Indicator showed a similar pattern. In of the 208 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on May 05, 2026. You may want to consider a long position or call options on ALKS as a result. In of 98 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for ALKS just turned positive on May 05, 2026. Looking at past instances where ALKS's MACD turned positive, the stock continued to rise in of 43 cases over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ALKS advanced for three days, in of 286 cases, the price rose further within the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
The 10-day RSI Indicator for ALKS moved out of overbought territory on May 15, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 35 similar instances where the indicator moved out of overbought territory. In of the 35 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 59 cases where ALKS's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ALKS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
ALKS broke above its upper Bollinger Band on May 12, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 90, placing this stock better than average.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ALKS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.539) is normal, around the industry mean (65.380). P/E Ratio (41.322) is within average values for comparable stocks, (60.348). ALKS's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.997). ALKS has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.030). P/S Ratio (4.002) is also within normal values, averaging (109.814).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of pharmaceutical products
Industry PharmaceuticalsGeneric